Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin

Yasuhiko Matsubayashi MD1 | Akihiro Yoshida PhD1,2 | Hideki Suganami PhD3 | Taeko Osawa MD1 | Kazuo Furukawa MD1 | Hiroshi Suzuki MD1 | Kazuya Fujihara1 | Shiro Tanaka PhD4 | Kohei Kaku MD5 | Hirohito Sone MD1

1Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan
2Kowa Company, Ltd, Tokyo, Japan
3Clinical Data Science Dept., Kowa Co., Ltd., Japan
4Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Japan
5Kawasaki Medical School, Okayama, Japan

Correspondence
Hirohito Sone, MD, Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Email: sone@med.niigata-u.ac.jp

Peer Review
The peer review history for this article is available at https://publons.com/publon/10.1111/dom.13980.

Abstract

Aims: Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose-cotransporter 2 inhibitors (SGLTis) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes. However, there are few reports of the influence of SGLT2is on hepatic insulin clearance. We examined the impact of an SGLT2i on hepatic insulin clearance and explored the clinical influence associated with changes in hepatic insulin clearance via an SGLT2i and the mechanism of the effects of SGLT2i.

Materials and methods: Data were analysed from 419 patients with type 2 diabetes controlled by diet and exercise. Patients received a placebo or the SGLT2i tofogliflozin (TOFO) (placebo: n = 56; TOFO: n = 363) orally once daily for ≥24 weeks. Hepatic insulin clearance was calculated from the ratio of areas under the curve (AUC) of C-peptide and insulin levels derived from oral meal tolerance test data (C-peptide AUC0-120 min/insulin AUC0-120 min: HICIR). The correlation of HICIR via the SGLT2i with other clinical variables was analysed using multivariate analysis.

Results: HICIR was significantly increased via TOFO at week 24. Furthermore, with TOFO insulin and triglyceride (TG) levels were significantly reduced (P < 0.001) and β-hydroxybutyrate (BHB) was significantly elevated (P < 0.001). Changes in HICIR were significantly correlated with changes in TG and BHB via TOFO.

Conclusions: Increased HICIR was significantly associated with reduced TG via TOFO and contributed to the greater increase in BHB compared with placebo in addition to the correction of hyperinsulinaemia.
1 | INTRODUCTION

Inhibition of renal glucose reabsorption by SGLT2 inhibitors (SGLT2-is) results in glycaemic improvement via an insulin-independent mechanism. Calorie loss by urinary glucose excretion (UGE) via SGLT2is leads to weight loss, improved insulin sensitivity and correction of hyperinsulinaemia. Epidemiological studies showed that inappropriate hyperinsulinaemia is a risk factor for atherosclerosis. In a meta-analysis in which blood insulin levels were reported, it was concluded that hyperinsulinaemia is a risk factor for cardiovascular disease. Diminished hepatic insulin clearance resulting from obesity and hepatic fat accumulation are among the causes of inappropriate hyperinsulinaemia and insulin resistance. Therefore, regulating hepatic insulin clearance and correcting hyperinsulinaemia are important therapeutic targets in patients with type 2 diabetes and insulin resistance. SGLT2is were reported to increase circulating levels of β-hydroxybutyrate (BHB). An increase in BHB via SGLT2is was associated with decreases in the plasma insulin level and the insulin-to-glucagon ratio. Therefore, the impact of SGLT2is on hepatic insulin clearance, which is one of the regulators of insulin levels, may be attributed to increases in BHB via SGLT2is. However, reports of the evaluation of the impact of SGLT2is on hepatic insulin clearance and other influences related to hepatic insulin clearance changes via SGLT2is are scarce. Therefore, the aim of this study was to investigate the impact of an SGLT2i on hepatic insulin clearance and to explore its linkage with simultaneous changes in clinical parameters via SGLT2i in drug-naïve patients with type 2 diabetes enrolled in Phase 2 and 3 studies of tofogliflozin (TOFO).

2 | MATERIALS AND METHODS

This was a pooled analysis to evaluate the impact on hepatic insulin clearance by SGLT2 inhibition from two prospective Phase 2 and 3 studies (Table S1; see Supporting Information). The duration of these studies was at least 24 weeks and they enrolled patients with type 2 diabetes not taking glucose-lowering agents to compare a placebo to placebo-controlled, combined Phase 2 and 3 study. The CSG004JP study (placebo, TOFO 10, 20 and 40 mg monotherapy) was a 24-week randomized, double-blind, placebo-controlled, combined Phase 2 and 3 study. The CSG004JP study (TOFO 20 and 40 mg monotherapy) was a 52-week randomized-controlled, open-label, Phase 3 study. Details of those studies were previously reported. Data from the 24-week core treatment period in each study were included in this pooled analysis.

All studies were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation (ICH) Good Clinical Practice. The protocols were reviewed and approved by the institutional review board of each participating centre. All patients provided written informed consent to participate in the study before enrolment.

In this post-hoc study to investigate the association of hepatic insulin clearance leading to a shift in insulin levels, BHB and triglyceride (TG), we focused on clinical indicators [e.g. liver enzymes, lipids, incretin, index related to fatty liver (FL), insulin resistance/sensitivity] and performed the analysis as described below.

Baseline characteristics of study participants are shown in Table S1 and S2 (see Supporting Information). Laboratory variables measured at baseline were glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), fasting C-peptide, fasting insulin (fasting IRI), fasting glucagon, glucagon-like peptide-1 (GLP-1), homeostatic model assessment of insulin resistance (HOMA-IR) scores, 24-variable HOMA for β-cell function and insulin sensitivity (HOMA2: iHOMA2%B and iHOMA2%S), the Matsuda index (10 000/square root of [fasting glucose (mg/dL) × fasting insulin (μU/mL) × mean glucose × mean insulin]) by the meal tolerance test (MTT) D-120min adiponectin, free fatty acids (FFA), BHB, hepatic enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT)] and γ-glutamyl transpeptidase (γGTP), serum lipids (LDL-C, HDL-C and TG), and the estimated glomerular filtration rate calculated from serum creatinine (eGFR). A standardized MTT was performed at baseline and week 24. Postprandial glucose, IRI and C-peptide were evaluated as glucose area under the curve (AUC)D-120min, IRI AUCD-120min and C-peptide AUCD-120min respectively. Hepatic insulin clearance was calculated as the ratio of AUC of C-peptide and IRI derived from MTT data (C-peptide AUCD-120 min/IRI AUCD-120 min: HICCRP). C-peptide and IRI are co-secreted in equimolar amounts from the pancreas to the portal vein. IRI but not C-peptide is partially metabolized in the liver and flows into the peripheral circulation. On the other hand, C-peptide flows into the peripheral circulation without being metabolized in the liver. Therefore, we could evaluate hepatic insulin clearance as the HICCRP. In addition, assessments at baseline and 24 weeks after administration of TOFO or placebo included body weight, body mass index (BMI) and waist circumference.

As in our previous report, the presence of FL was estimated using a cut-off value based on the FL index (FLI) [e0.953 × loge (TG) + 0.139 × BMI + 0.718 × loge (γGTP) + 0.053 × waist circumference − 15.745]/(1 + e0.953 × loge (TG) + 0.139 × BMI + 0.718 × loge (γGTP) × 0.053 × waist circumference − 15.745 × 100. An FLI ≥35 for males and ≥20 for females determined the presence of FL, while an FLI <35 for males and <20 for females ruled out FL according to a report targeting over 30 000 Asians. In this report, the FLI had excellent discriminative ability to detect patients with ultrasonographic FL (positive likelihood ratio 3.12 for males and 4.43 for females).

To assess the influence of the changes in HICCRP via TOFO, study participants receiving TOFO were divided into quartiles (Q) according to the percentage change from baseline in HICCRP (%ΔHICCRP) at week 24 after administration of TOFO (Q1-Q4) (Table 1). The group with the lowest value of %ΔHICCRP was designated as the Q1 group and the group with the highest such value was designated as the Q4 group.

2.1 | Meal tolerance test

Details of the protocol for the MTT were previously described. In short, after fasting for at least 10 h, participants attended the medical institution participating in the clinical trials and underwent an MTT with a test meal. The test meal provided 314 kcal/1314 kJ (5.45 g protein, 73.05 g carbohydrate and 0 g lipids).
| TABLE 1 | Baseline characteristics according to quartiles of percentage change in HIC$_{CIR}$ at week 24 after administration of tofogliflozin |
|---------|---------------------------------------------------------------------------------------------------------------|
|         | Quartile 1 (%Δ HIC$_{CIR}$ $< +5.5$) | Quartile 2 (+5.5 ≤ %Δ HIC$_{CIR}$ $< +20.5$) | Quartile 3 (+20.5 ≤ %Δ HIC$_{CIR}$ $< +35.5$) | Quartile 4 (+35.5 ≤ %Δ HIC$_{CIR}$) | P |
| N       | 76 | 76 | 77 | 76 |
| Age (years) | 55.1 (11.5) | 59.6 (9.8) | 58.1 (9.3) | 58.1 (9.8) | 0.048 |
| Sex, men/women, n (%) | 60 (78.9)/16 (21.1) | 44 (57.9)/32 (42.1) | 45 (58.4)/32 (41.6) | 50 (65.8)/26 (34.2) | 0.02 |
| Tofogliflozin, n(%) 10/20/40 mg | 9 (11.8)/20 (26.3)/47 (61.8) | 16 (21.1)/21 (27.6)/39 (51.3) | 11 (14.3)/29 (37.7)/37 (48.1) | 9 (11.8)/28 (36.8)/39 (51.3) | 0.35 |
| Fatty liver index$^b$ | 43.5 (30.1) | 44.7 (25.4) | 50.0 (27.8) | 44.1 (27.6) | 0.44 |
| Fatty liver, n (%) | 43 (56.6) | 51 (67.1) | 55 (71.4) | 45 (59.2) | 0.20 |
| Duration of diabetes (years) | 5.8 (5.4) | 5.8 (5.3) | 6.4 (6.7) | 5.4 (4.9) | 0.73 |
| eGFR (mL/min/1.73 m$^2$) | 85.3 (20.4) | 83.3 (19.7) | 85.8 (19.3) | 84.8 (17.2) | 0.86 |
| Body weight (kg) | 71.3 (16.8) | 67.1 (12.5) | 67.0 (12.2) | 67.6 (13.5) | 0.18 |
| Waist circumference (cm) | 90.0 (13.1) | 88.7 (8.5) | 89.4 (9.8) | 88.5 (10.0) | 0.80 |
| BMI (kg/m$^2$) | 25.4 (4.4) | 25.3 (3.4) | 25.5 (4.0) | 25.2 (4.5) | 0.95 |
| HbA1c (%) | 8.3 (1.0) | 7.9 (0.7) | 8.1 (0.8) | 7.9 (0.8) | 0.01 |
| Fasting plasma glucose (mg/dL) | 166.8 (41.7) | 156.3 (22.7) | 162.3 (34.3) | 155.3 (30.5) | 0.11 |
| Fasting insulin (pmol/L) | 49.4 (38.7) | 54.6 (31.5) | 49.8 (31.8) | 60.2 (60.1) | 0.36 |
| Fasting C-peptide (pmol/L) | 474.3 (221.4) | 487.4 (208.5) | 460.0 (196.7) | 464.3 (205.3) | 0.85 |
| Fasting glucagon (pmol/L) | 20.1 (5.4) | 19.8 (4.9) | 19.3 (4.4) | 20.0 (5.3) | 0.74 |
| Glucose AUC$_{0-120min}$ (mg/dL·2 h) | 526.3 (123.3) | 505.8 (80.6) | 513.9 (91.6) | 499.4 (87.8) | 0.36 |
| Insulin AUC$_{0-120min}$ (pmol/L·2 h) | 279.5 (160.4) | 373.9 (209.0) | 401.9 (279.5) | 439.2 (297.6) | <0.001 |
| C-peptide AUC$_{0-120min}$ (pmol/L·2 h) | 1897.9 (675.4) | 2157.1 (799.5) | 2203.2 (845.8) | 2163.9 (797.3) | 0.06 |
| Glucagon AUC$_{0-120min}$ (pmol/L·2 h) | 41.4 (10.3) | 40.3 (9.5) | 39.6 (8.1) | 40.3 (10.1) | 0.71 |
| HIC$_{CIR}$ | 7.6 (2.0) | 6.5 (1.9) | 6.6 (2.4) | 6.0 (2.2) | <0.001 |
| Total GLP-1 AUC$_{0-120min}$ (pmol/L·2 h) | 19.2 (15.2) | 17.7 (7.2) | 18.8 (6.6) | 18.5 (7.4) | 0.81 |
| Active GLP-1 AUC$_{0-120min}$ (pmol/L·2 h) | 4.6 (5.2) | 4.0 (1.9) | 4.4 (1.9) | 4.1 (1.9) | 0.61 |
| HOMA-IR$^d$ | 3.4 (2.6) | 3.5 (2.2) | 3.3 (2.1) | 3.9 (4.0) | 0.62 |
| iHOMA2%S$^e$ | 140.9 (97.0) | 119.6 (79.5) | 131.3 (79.4) | 129.2 (84.8) | 0.50 |
| iHOMA2%B$^e$ | 29.2 (19.5) | 33.2 (16.3) | 31.7 (23.7) | 36.1 (24.9) | 0.25 |
| Matsuda index | 5.1 (3.3) | 4.1 (2.6) | 4.3 (2.7) | 4.2 (2.7) | 0.13 |
| LDL-C (mg/dL) | 118.7 (32.9) | 126.2 (26.0) | 129.6 (34.4) | 124.8 (28.9) | 0.17 |
| HDL-C (mg/dL) | 58.7 (17.0) | 58.1 (18.1) | 59.6 (15.2) | 60.2 (17.4) | 0.88 |
| Ln-TG (ln[mg/dL]) | 4.8 (0.7) | 4.9 (0.5) | 5.0 (0.6) | 4.9 (0.6) | 0.10 |
| AST (IU/L) | 25.4 (9.5) | 25.8 (8.8) | 27.5 (11.2) | 24.7 (7.8) | 0.31 |
| ALT (IU/L) | 29.6 (18.4) | 28.9 (14.1) | 30.7 (18.9) | 27.0 (14.2) | 0.57 |
| γGTP (IU/L) | 50.2 (76.5) | 45.1 (41.0) | 52.5 (55.0) | 43.4 (34.4) | 0.70 |

(Continues)
2.2 Statistical analysis

The adjusted assessment of HICCIR was analysed using an analysis of covariance (ANCOVA) model with the group (placebo or TOFO) as a fixed effect and their baseline values as covariates. Similarly, changes in the other variables with the participant in fasting and postprandial states were analysed using an ANCOVA model. To assess the association of TOFO dosage with changes in variables, the adjusted variables were analysed using an ANCOVA model with the group (TOFO 10, 20 or 40 mg) as a fixed effect and baseline values of each group as covariates. The difference from baseline to week 24 was analysed by a one-sample t-test. The correlation analysis at week 24 was performed using Pearson product-moment correlation coefficients. We also performed multivariate analyses to explore clinical variables that might independently correlate with changes in ln-transformed BHB (ln-BHB) and %HICCIR from baseline to week 24 in the participants receiving TOFO. All variables initially identified based on clinical considerations were used as explanatory variables in these multivariate analyses (Table 3, and Tables S5-S7; see Supporting Information). The model was simplified using a stepwise method by increasing and decreasing variables that were P < 0.05. The characteristics of study participants were summarized with appropriate descriptive statistics (means ± SD for continuous variables and counts and percentages for categorical variables). Differences in the baseline assessments between the placebo and TOFO groups were analysed by the unpaired t-test or the Fisher’s exact test. Baseline differences in the assessments between quartiles according to %HICCIR at week 24 after administration of TOFO were analysed by one-way analysis of variance (ANOVA) or Fisher’s exact test across groups. The adjusted changes in variables, specifically, HbA1c, FPG, glucose AUC0-120min by MTT, body weight, waist circumference, fasting FFA, adiponectin, LDL-C, HDL-C, TG, hepatic enzymes and FLI, according to quartiles of %HICCIR at week 24 after administration of TOFO were analysed using an ANCOVA model with the groups (quartiles) as a fixed effect and their baseline values as covariates. From those analyses, we evaluated P values corresponding to the groups using the F-test and simultaneously performed t-tests using estimated least squares means in each group based on these models of analysis. Analyses also were performed by ANOVA across quartiles for the following variables: fasting IRI, fasting C-peptide, fasting glucagon, IRI AUC0-120min, C-peptide AUC0-120min, glucose AUC0-120min, HICCIR, total GLP-1 AUC0-120min, active GLP-1 AUC0-120min, Matsuda index, iHOMA2%S and iHOMA2%. The proportion of FL was analysed by Fisher’s exact test. All HbA1c values are presented using NGSP units. The (two-sided) significance level for each test was 0.05. All data were analysed by SAS release 9.3 software (SAS Institute, Cary, NC, USA).

3 RESULTS

HICCIR and serum BHB were significantly increased in the TOFO group (P < 0.001 vs. baseline, P < 0.001 vs. placebo) at week 24 (Table S3; see Supporting Information). In addition, significant
| Variables                          | Quartile 1 (%Δ HIC_Cir < +5.5) | Quartile 2 (+5.5 ≤ %Δ HIC_Cir < +20.5) | Quartile 3 (+20.5 ≤ %Δ HIC_Cir < +35.5) | Quartile 4 (+35.5 ≤ %Δ HIC_Cir) | P       |
|-----------------------------------|--------------------------------|----------------------------------------|------------------------------------------|---------------------------------|---------|
| N                                 | 76                            | 76                                     | 77                                      | 76                             |         |
| Fasting insulin (%)               | −5.5 (3.3)                    | −24.9 (3.3)***                        | −237 (3.3)***                           | −31.1 (3.3)***                  | <0.001  |
| Fasting C-peptide (%)             | −5.3 (2.7)*                   | −10.7 (2.7)***                        | −100 (2.7)***                           | −9.8 (2.7)***                   | 0.49    |
| Fasting glucagon (%)              | 0.59 (2.08)                   | −21.8 (2.08)                           | 1.53 (2.07)                             | −2.10 (2.08)                   | 0.48    |
| Insulin AUC_120min (%)            | 17.4 (2.2)***                 | −10.2 (2.2)***                        | −19.4 (2.1)***                          | −30.6 (2.2)***                  | <0.001  |
| C-peptide AUC_120min (%)          | 11.3 (2.3)***                 | 1.8 (2.3)                              | 3.3 (2.3)                               | 3.4 (2.3)                       | 0.02    |
| Glucagon AUC_120min (%)           | −4.1 (1.7)*                   | −2.3 (1.7)                             | −2.3 (1.7)                              | −3.7 (1.7)***                   | 0.81    |
| HIC_Cir (%)                       | −4.4 (1.0)***                 | 13.5 (1.0)***                         | 28.2 (1.0)**                            | 50.1 (1.0)***                   | <0.001  |
| Total GLP-1 AUC_120min (%)        | 7.2 (4.3)                     | 6.5 (4.3)                              | 2.1 (4.3)                               | 4.2 (4.3)                       | 0.83    |
| Active GLP-1 AUC_120min (%)       | 241.5 (51.1)***               | 27.6 (5.1)***                         | 28.9 (5.0)**                            | 41.4 (5.1)***                   | 0.09    |
| Matsuda index (%)                 | 32.9 (5.6)***                 | 64.6 (5.6)***                         | 70.2 (5.6)***                           | 92.7 (5.6)***                   | <0.001  |
| iHOMA2%S (%)                      | 27.7 (5.9)***                 | 53.3 (5.9)***                         | 51.1 (5.8)***                           | 64.6 (5.9)***                   | <0.001  |
| iHOMA2%β (%)                      | 65.8 (7.3)***                 | 26.1 (7.3)***                         | 32.2 (7.3)**                            | 19.9 (7.3)***                   | <0.001  |
| HbA1c (%)                         | −0.88 (0.06)***               | −0.80 (0.06)***                       | −0.74 (0.06)***                         | −0.73 (0.06)***                 | 0.23    |
| Fasting plasma glucose (mg/dL)    | −32.9 (1.9)***                | −33.2 (1.9)***                        | −30.6 (1.9)***                          | −32.4 (1.9)***                  | 0.77    |
| Glucose AUC_120min (mg/dL/2 h)    | −112.3 (5.6)***               | −140.0 (5.6)***                       | −98.5 (5.6)***                          | −103.7 (5.6)***                 | 0.29    |
| Body weight (%)                   | −3.4 (0.3)***                 | −4.8 (0.3)***                         | −4.5 (0.3)***                           | −4.9 (0.3)***                   | <0.01   |
| Waist circumference (%)           | −2.7 (0.5)***                 | −2.3 (0.5)***                         | −2.8 (0.5)***                           | −3.0 (0.5)***                   | 0.69    |
| eGFR (%)                          | 4.4 (1.7)**                   | −1.2 (1.7)                             | 0.2 (1.6)                               | −0.9 (1.7)                      | 0.07    |
| LDL-C (%)                         | 1.3 (1.9)                     | −1.2 (1.9)                             | 0.9 (1.9)                               | −0.4 (1.9)                      | 0.77    |
| HDL-C (%)                         | 2.9 (1.6)                     | 5.1 (1.6)**                           | 7.9 (1.6)**                             | 10.5 (1.6)**                    | <0.01   |
| ln-TG (ln[mg/dL])                 | −0.06 (0.04)                  | −0.15 (0.04)**                        | −0.23 (0.04)**                          | −0.20 (0.04)**                  | 0.01    |
| AST (%)                           | −9.5 (2.1)***                 | −10.5 (2.1)***                        | −6.3 (2.1)***                           | −7.6 (2.1)***                   | 0.49    |
| ALT (%)                           | −14.3 (2.4)***                | −20.1 (2.6)***                        | −19.4 (2.6)***                          | −20.5 (2.6)***                  | 0.29    |
| γGTP (%)                          | −18.8 (2.9)***                | −21.9 (2.9)***                        | −20.0 (2.8)***                          | −19.0 (2.9)***                  | 0.86    |
| Fatty liver index (%)             | −18.3 (2.9)***                | −27.6 (2.9)***                        | −29.2 (2.9)***                          | −31.2 (2.9)***                  | 0.01    |
| Fatty liver at week 24, n (%)     | 37 (48.7)                     | 35 (46.1)                              | 44 (57.1)                               | 32 (42.1)                      | 0.30    |
| Fasting free fatty acid (%)       | 17.6 (5.6)***                 | 22.3 (5.6)***                         | 30.7 (5.6)***                           | 34.6 (5.6)***                   | 0.13    |
| Adiponectin (%)                   | 114 (2.2)***                  | 13.2 (2.2)***                         | 12.0 (2.2)***                           | 12.6 (2.2)***                   | 0.94    |
| ln-β-hydroxybutyrate (ln[mmol/L]) | 0.43 (0.09)***                | 0.61 (0.09)***                        | 0.75 (0.09)***                          | 0.82 (0.09)***                  | 0.02    |

Note: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; BMI, body mass index; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1; γGTP, γ-glutamyl transpeptidase; HbA1c, glycosylated haemoglobin; TG, triglycerides.
Data are expressed as mean (standard error).
Analyses were performed by ANOVA across quartiles for the following variables: fasting insulin, fasting C-peptide, fasting glucagon, insulin AUC_120min, C-peptide AUC_120min, glucagon AUC_120min, HIC_Cir, total GLP-1 AUC_120min, active GLP-1 AUC_120min, Matsuda index, iHOMA2%S and iHOMA2%β.
reductions in FPG, HbA1c, glucose AUC0-120min, IRI AUC0-120min and C-peptide AUC0-120min by MTT, body weight, waist circumference, hepatic enzymes and FLI were observed ($P < 0.001$ vs. baseline, $P < 0.001$ vs. placebo) in the TOFO group at week 24. In addition, a significant reduction in ln-TG was observed ($P < 0.001$ vs. baseline, $P < 0.01$ vs. placebo). As to changes in other variables from baseline to week 24, fasting IRI and fasting C-peptide were significantly decreased in the TOFO group compared with the placebo group ($P < 0.001$) (Table S3; see Supporting Information). Furthermore, with TOFO, iHOMA2%β ($P < 0.001$ vs. baseline, $P < 0.01$ vs. placebo) (Table S3; see Supporting Information). We analysed the effects on variables via TOFO at week 24 according to dosage (Table S4; see Supporting Information). HICCIR increased and ln-TG decreased significantly from baseline in each dosage group, but there were no statistically significant changes across dosage groups. A significant increase in ln-BHB was observed in each dosage group with significant differences across groups.

When the participants receiving TOFO were divided into quartiles according to %ΔHICCIR at week 24 after administration of TOFO, there were no significant differences in baseline characteristics across groups in BMI, insulin resistance/sensitivity index, FPG, hepatic enzymes, FLI, serum lipids, eGFR and C-peptide AUC0-120min using MTT but there were significant differences in age, sex ratio, HbA1c, ln-BHB, HIC CIR and IRI AUC0-120min using MTT (Table 1). As to changes in variables according to quartiles of %ΔHICCIR at week 24 after administration of TOFO, in the order of Q4-Q1 greater reductions in the percentage changes (%Δ) in body weight, fasting IRI, IRI AUC0-120min, C-peptide AUC0-120min using MTT and FLI were observed (Table 2). In addition, there was a significant increase in ln-BHB was observed in each dosage group with significant differences across groups.

### TABLE 3  Factors that might independently correlate with change in ln-β-hydroxybutyrate at week 24

| Factors that might independently correlate with Δln-β-hydroxybutyrate at week 24 | Regression coefficient | P  |
|---------------------------------------------------------------------------------|------------------------|----|
| %Δ fasting free fatty acid (increase 10%)                                      | 0.10                   | <0.001 |
| %Δ HICCIRa (increase 10%)                                                       | 0.04                   | 0.02  |
| %Δ iHOMA2%Sb (increase 10%)                                                     | 0.03                   | <0.001 |
| Δ ln-TG (increase 0.1 ln[mg/dL])                                                | −0.05                  | >0.05  |

Note: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1; TG, triglyceride.

Factors remained through stepwise variable selection with $P < 0.05$. Potential baseline predictors were age, sex, duration of diabetes, change in glycated haemoglobin and ln-transformed TG from baseline to week 24 and the percentage change in the following variables from baseline to week 24: eGFR, body weight, waist circumference, fasting plasma glucose, glucose AUC0-120min, active GLP-1 AUC0-120min, HICCIR, adiponectin, fasting free fatty acid, AST, ALT, yGTP, iHOMA2Sa and iHOMA2Sb.

aC-peptide AUC0-120min/insulin AUC0-120min ratio.

bFrom the iHOMA2 model.
significant difference across quartiles in the amount of change in ln-TG (Q1: -0.06; Q2: -0.15; Q3: -0.23; Q4: -0.20, \( P = 0.01 \)) (Table 2). Furthermore, the degree of change in ln-BHB, and \( %\Delta \text{iHOMA2%S} \) and \( %\Delta \text{Matsuda index} \) significantly increased in the order of Q4-Q1 (Table 2). Correlation analysis indicated a significant negative relationship between \( %\Delta \text{HICCIR} \) and change in ln-TG (\( r = -0.23 \)) (Figure 1A), ln-BHB and ln-TG (\( r = -0.27 \)) (Figure 1D) at week 24 after administration of TOFO. On the other hand, significant positive relationships between \( %\Delta \text{HICCIR} \) and \( %\Delta \text{active GLP-1 AUC}_{0-120\text{min}} \) by MTT (\( r = 0.15 \)) or change in ln-BHB (\( r = 0.28 \)) were observed (Figure 1B and 1C). In addition, significant correlations were observed between changes in ln-BHB and indicators related to plasma glucose, insulin levels, fasting FFA, eGFR and FLI (Table S5; see Supporting Information). Multivariate analysis indicated that the change in ln-BHB was independently correlated with \( %\Delta \text{HICCIR} \), \( %\Delta \text{fasting FFA} \), \( %\Delta \text{iHOMA2%S} \) and change in ln-TG (Table 3). In addition, \( %\Delta \text{HICCIR} \) was independently correlated with \( %\Delta \text{iHOMA2%S} \), \( %\Delta \text{GFR} \), \( %\Delta \text{active GLP-1 AUC}_{0-120\text{min}} \), and change in HbA1c, ln-BHB and ln-TG by univariate and multivariate analyses (Tables S6 and S7; see Supporting Information).

**DISCUSSION**

To the best of our knowledge, this study is the first to evaluate the impact of changes in HICCIR via SGLT2 inhibition and to explore the linkage of changes in HICCIR with that of TG and BHB via an SGLT2i in drug-naïve patients with type 2 diabetes.

Insulin resistance caused by weight gain and visceral fat accumulation may lead to hyperinsulinaemia, which might prompt not only further weight gain but also cardiometabolic disorders associated with the risk of cardiovascular disease.\(^{19}\) A decline in hepatic insulin clearance is one of the causes of hyperinsulinaemia.\(^{20}\) In a study of obese individuals without diabetes, it was shown that the insulin clearance rate might decrease before the insulin secretion rate increases as a compensatory mechanism when insulin sensitivity decreases.\(^{21}\) Furthermore, a decline in hepatic insulin clearance was observed from the early stages of type 2 diabetes.\(^{22}\) In particular, the presence of FL\(^23\) and type 2 diabetes\(^24\) decreased hepatic insulin clearance. Therefore, optimization of hepatic insulin clearance is considered useful to prevent various metabolic disorders, including glucose intolerance and complications caused by inappropriate hyperinsulinaemia. Previously, reports that various interventions might influence hepatic insulin...
clearance have been scant. Weight reduction26 and antidiabetic agents such as a biguanide26 and thiazolidinediones27 increased hepatic insulin clearance, whereas sulphonylureas28 decreased hepatic insulin clearance. Results of the current study indicated that SGLT2 inhibition significantly increased HICCIR at week 24 (Table S3; see Supporting Information). However, identifying patients who tended to have increased HICCIR via SGLT2-i was difficult in performing this study. This is because the baseline characteristics according to quartiles of % ΔHICCIR via TOFO were very similar across the groups except for baseline HICCIR, age, sex ratio, Hba1c and ln-BHB (Table 1). In addition, the mechanism by which SGLT2-i is induced the increases in hepatic insulin clearance has not been clarified. However, of interest is a report that excess carbohydrate intake elevated plasma TG concentration and reduced insulin clearance.29 Data have shown a significant negative correlation between diet-induced changes in fasting plasma TG concentration and changes in insulin clearance.29,30 Fasting plasma VLDL-TG concentration reflects hepatic TG content,31 and it has been speculated that the increase in intrahepatic TG accumulation associated with the intake of a high-carbohydrate diet is directly linked to decreased hepatic insulin clearance. The decreased hepatic insulin clearance because of a high-carbohydrate diet may be associated with reduced expression of the glycoprotein carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) through such a high-carbohydrate diet.30 CEACAM1 promotes hepatic insulin endocytosis and hepatic insulin clearance and, hence, maintains systemic insulin sensitivity.32 The present study indicated that there was a significant negative correlation between the % ΔHICCIR and the change in ln-TG after TOFO administration (Figure 1A). In addition, increased % ΔHICCIR or a change in ln-TG via TOFO was significantly correlated with the increase in serum BHB reflecting lipolysis associated with decreased insulin levels (Figure 1C and 1D). These independent correlations among HICCIR, TG and BHB were revealed by multivariate analysis (Table 3). FLI also improved significantly in the order of Q4-Q1 after TOFO administration (Figure 1A and Table 2). These results provided support for the suggestion calorie loss due to UGE by the SGLT2i has an effect similar to that of a carbohydrate-restricted diet, and the improvement of FLI or TG via TOFO in the order of Q4-Q1 suggested that TOFO increases HICCIR through reduction of intrahepatic TG and improvement in FL. We also previously indicated that the influence of FL was a stronger contributor than obesity to reduced hepatic insulin clearance.36 Therefore, SGLT2 inhibition might normalize the inappropriate hyperinsulinaemia in type 2 diabetes by correcting disorders of hepatic insulin clearance through improvement of FL, including reduction of intrahepatic TG content along with plasma TG concentration. Further investigation will be needed to clarify the mechanism by which SGLT2is increase hepatic insulin clearance. Interestingly, there was a significant positive correlation between % ΔHICCIR and % Δactive GLP-1 AUCo-120min but not total GLP-1 AUCO-120min via TOFO (Figure 1B). In addition, multivariate analysis indicated that the increase in % ΔHICCIR was independently correlated with the increase in % Δactive GLP-1 AUCO-120min (Table S7; see Supporting Information). Although it is difficult to clarify this mechanism in the present study, a previous study indicated that dapagliflozin administration reduced the serum level of soluble dipeptidyl peptidase-4 (sDPP-4) in patients with type 2 diabetes with non-alcoholic FL disease33; therefore, a decrease in serum sDPP-4 via an SGLT2i may be partly involved.

A previous study that examined the association between hepatic insulin clearance and FPG levels in participants with type 2 diabetes and impaired glucose tolerance revealed no significant correlation between hepatic insulin clearance and FPG levels.34 That report suggests that changes in hepatic insulin clearance do not necessarily correlate with plasma glucose levels. In fact, multivariate analysis showed that changes in fasting glucose and A glucose AUCo-120min using MTT were not independent factors (Table S7; see Supporting Information). On the other hand, multivariate analysis also showed that the decrease in Hba1c via TOFO was independently correlated with the decrease in percentage change in HICCIR (Tables S6 and S7; see Supporting Information). We could not clarify the mechanism of this association in the current study. A future prospective study will be needed.

Interestingly, euglycaemic ketoacidosis was reported as a specific side effect of SGLT2is.35 Although details of the mechanism of this side effect have not been clarified, the increased HICCIR levels leading to the decreased blood insulin, which occurred independently of the decrease in blood glucose accompanied by the administration of SGLT2-i, may be partly responsible for this side effect. To support this hypothesis, the present study showed a significant positive relationship between an increase in % ΔHICCIR and BHB via TOFO (Figure 1C). Furthermore, an independent relationship between those factors was observed in the multivariate analysis (Table 3). However, an elevation of BHB via an SGLT2i also has been suggested to be a benefit. Recent studies suggested that BHB might be cardioprotective because BHB is freely taken up by the heart and is oxidized in priority to FFA and that in the myocardium, the use of ketone bodies might be energy efficient through improving oxygen consumption.36

As mentioned above, in general, decreases in hepatic insulin clearance are because of a metabolic abnormality such as obesity or FL but genetic factors may be involved in high hepatic insulin clearance values.22 In recent years, genome-wide association studies have revealed several single nucleotide polymorphisms related to susceptibility to type 2 diabetes. It was reported that common variants of the solute carrier family 30 member 8 gene (SLC30A8) increase the susceptibility to type 2 diabetes.37 Zinc (Zn) is required for the formation of the zinc transporter-8 (ZnT8) is a transporter that transports Zn from the cytosol to the intragranular spaces in insulin. SLC30A8 encodes ZnT8. It became clear that hepatic insulin clearance was increased in human carriers of rs13266634, which is a major risk allele of SLC30A8.38 Thus, future study is needed to clarify how the increase in hepatic insulin clearance related to the administration of an SGLT2i affects metabolism in patients with type 2 diabetes who have this risk allele.

The current study has some limitations. First, it was an integrated analysis that included prospective studies of participants with limited information on their baseline characteristics. In addition, the number of participants receiving each dosage of TOFO was limited and
unbalanced for a sufficient evaluation of dosage response related to variables. Secondly, insulin sensitivity was not evaluated using insulin-clamp methods. Thirdly, HIC\textsubscript{CR} was a surrogate estimate of hepatic insulin clearance, not a direct measurement of hepatic insulin clearance. Therefore, we could not investigate precisely the biological and pathological effects via TOFO on hepatic insulin clearance or insulin sensitivity. Fourthly, it is debatable whether weight loss and improved insulin sensitivity are primary antidiabetic actions of SGLT2is or effects secondary to the improved glycaemic control via SGLT2is. Unfortunately, we could not elucidate this point sufficiently in the current study. Finally, we have not been able to examine genes among participants that would affect hepatic insulin clearance.

In conclusion, this study indicated that an SGLT2i might improve inappropriate hyperinsulinaemia by increasing HIC\textsubscript{CR}. Also suggested was that increases in HIC\textsubscript{CR} via the SGLT2i were related to decreases in plasma TG concentration (reflecting reduction of intrahepatic TG content and improving FL) and elevated plasma BHB levels via the SGLT2i. Inappropriate hyperinsulinaemia is associated with various adverse events, including cardiovascular events. On the other hand, SGLT2is have shown to have a protective effect on the heart and kidney and to suppress some of these adverse events. Dysregulation of hepatic insulin clearance is one of the important pathophysologies observed in various conditions in which there are metabolic abnormalities, including type 2 diabetes, obesity and FL. Therefore, our study clarified how an SGLT2i affected HIC\textsubscript{CR} and indicated that the relationship between changes in HIC\textsubscript{CR} and other clinical parameters, including BHB via an SGLT2i, is important for a partial understanding of the mechanism of the multifaceted effect of this drug, including its cardioprotective or renal protective effect revealed in recent trials. Further studies to clarify the mechanism of changes in hepatic insulin clearance and impact of such changes via an SGLT2i on the clinical course should be conducted.

ACKNOWLEDGMENTS

We sincerely acknowledge all participants in the TOFO studies.

ORCID

Yasuhiro Matsubayashi https://orcid.org/0000-0002-2143-1921
Akihiro Yoshida https://orcid.org/0000-0002-0573-5298
Hideki Suganami https://orcid.org/0000-0001-9130-0137
Kazuya Fujihara https://orcid.org/0000-0002-5777-4686
Kohei Kaku https://orcid.org/0000-0003-1574-0565

REFERENCES

1. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495-502.
2. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-514.
3. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.
4. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952-957.
5. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97(10):1096-1110.
6. Marini MA, Frontoni S, Saccuccio E, et al. Differences in insulin clearance between metabolically healthy and unhealthy obese subjects. Acta Diabetol. 2014;51(2):257-261.
7. Kotronen A, Juurinen L, Tiihkainen M, Vehkavaara S, Yki-Jarvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology. 2008;135(1):122-130.
8. Praticchizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20(11):2515-2522.
9. Ferrannini E, Baldi S, Frascerra S, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016;65(5):1190-1195.
10. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.
11. Tanizawa Y, Kaku K, Arai E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15(6):749-766.
12. Hill NR, Levy JC, Matthews DR. Expansion of the homeostasis model assessment of beta-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetes Care. 2013;36(8):2324-2330.
13. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462-1470.
14. Pivovarova O, Bernigau W, Bobbert T, et al. Hepatic insulin clearance is closely related to metabolic syndrome components. Diabetes Care. 2013;36(11):3779-3785.
15. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes. 1994;43(5):486-494.
16. Matsubayashi Y, Yoshida A, Suganami H, et al. Role of fatty liver in the association between obesity and reduced hepatic insulin clearance. Diabetes Metab. 2018;44(2):135-142.
17. Bedogni G, Bellantani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
18. Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index. Hepatology. 2014;59(2):567-575.
19. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuniga FA. Association between insulin resistance and the development of cardiovascular disease. Acta Diabetol. 2013;50(1):377-385.
23. Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md). 2014;59(6):2178-2187.

24. Ohashi K, Komada H, Uda S, et al. Glucose Homeostatic Law: Insulin Clearance Predicts the Progression of Glucose Intolerance in Humans. PLoS one. 2015;10(12):e0143880.

25. Henry RR, Brechtel G, Griver K. Secretion and hepatic extraction of insulin after weight loss in obese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1988;66(5):979-986.

26. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003;88(1):148-156.

27. Osei K, Gaillard T, Schuster D. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone Metabolism: clinical and experimental. 2007;56(1):24-29.

28. Osei K, Rhinesmith S, Gaillard T, Schuster D. Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action. Metabolism: clinical and experimental. 2003;52(5):565-572.

29. Lundsgaard AM, Sjoberg KA, Hoeg LD, et al. Opposite Regulation of Insulin Sensitivity by Dietary Lipid Versus Carbohydrate Excess. Diabetes. 2017;66(10):2583-2595.

30. Bojsen-Moller KN, Lundsgaard AM, Madsbad S, Kiens B, Holst JJ. Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations-Rule of Carbohydrate and Energy Availability. Diabetes. 2018;67(11):2129-2136.

31. Mittendorfer B, Yoshino M, Patterson BW, Klein S. VLDL Triglyceride Kinetics in Lean, Overweight, and Obese Men and Women. J Clin Endocrinol Metab. 2016;101(11):4151-4160.

32. DeAngelis AM, Heinrich G, Dai T, et al. Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes. 2008;57(9):2296-2303.

33. Aso Y, Kato K, Sakurai S, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019;73:e13335.

34. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care. 2018;41(8):1696-1706.

35. Meyer EJ, Gabb G, Jesudason D. SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications. Diabetes Care. 2018;41(4):e47-e49.

36. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39(7):1108-1114.

37. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (New York, NY) 2007;316(5829):1331-1336.

38. Tamaki M, Fujitani Y, Hara A, et al. The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance. J Clin Invest. 2013;123(10):4513-4524.

39. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial. Circulation. 2019;140:739-750.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Matsubayashi Y, Yoshida A, Suganami H, et al. Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. Diabetes Obes Metab. 2020;22:947-956. https://doi.org/10.1111/dom.13980